Biofrontera Inc. Ratios | P/E, ROE & Valuation

On the Key Ratios page for Biofrontera Inc. (BFRI), the latest P/E of -2.5 frames valuation, while ROE -127.78% and ROIC -31.18% indicates profitability and capital efficiency. Together with the current ratio of 1.18 and debt-to-equity 1.26, these signals help you judge whether valuation is supported by fundamentals across the historical rows.

Financial Performance Ratios

BFRI Historical Per Share Metrics

7 years
Metric (FY)TTM202420232022202120202019
Revenue per Share$3.57$6.76$22.03$27.13$28.18$32.50$43.13
Net Income per Share$-0.49$-3.22$-13.02$-0.61$-44.10$-18.94$-18.09
Operating Cash Flow per Share$-0.61$-1.86$-16.10$-15.33$-31.24$-21.33$-62.07
Free Cash Flow per Share$-0.61$-1.86$-16.10$-15.36$-31.25$-21.33$-62.96
Cash per Share$0.36$1.07$0.92$26.26$28.70$13.93$12.03
Book Value per Share$0.46$0.80$3.10$22.59$13.26$10.05$-49.72
Tangible Book Value per Share$0.26$0.80$1.40$19.72$9.22$3.38$-56.78
Interest Debt per Share$0.60$1.27$3.88$1.62$0.42$4.99$66.49
CAPEX per Share$0.00$0.00$0.00$0.04$0.01$0.00$0.89

BFRI Historical Valuation Ratios

7 years
Metric (FY)TTM202420232022202120202019
Price to Earnings (P/E)-2.53-0.34-0.21-30.29-3.41-4.66-4.88
Price to Book (P/B)3.31.360.890.8111.348.78-1.77
Price to Sales (P/S)0.420.160.130.685.342.712.04
Enterprise Value to EBITDA-3.96-0.35-0.453.77-2.83-5.75-10.36
EV to Sales0.480.130.240.124.322.293.23
EV to Operating Cash Flow-2.81-0.49-0.33-0.22-3.9-3.48-2.24
EV to Free Cash Flow-2.81-0.49-0.33-0.22-3.89-3.48-2.21
Enterprise Value$22.31M$5.03M$8.34M$3.52M$104.08M$43.08M$84.44M

BFRI Historical Profitability Ratios

7 years
Metric (FY)TTM202420232022202120202019
Return on Equity (ROE)-127.78%-400.61%-420.01%-2.68%-332.62%-188.52%36.39%
Return on Invested Capital (ROIC)-31.18%-162.13%-157.16%-63.12%-64.08%-42.51%-87.99%
Return on Tangible Assets-29.61%-80.48%-79.56%-1.34%-75.78%-54.21%-44.89%
Earnings Yield-32.40%-295.35%-469.99%-3.30%-29.32%-21.48%-20.51%
Free Cash Flow Yield-40.75%-170.97%-581.34%-83.76%-20.78%-24.18%-71.38%
Dividend Yield0.00%0.00%0.00%0.00%0.00%0.00%0.00%

BFRI Historical Liquidity & Financial Strength

7 years
Metric (FY)TTM202420232022202120202019
Current Ratio1.181.721.282.063.364.432
Interest Coverage-18.81-8.17-37.8-50.22-70-2.88-6.91
Income Quality1.250.581.2425.310.711.133.43
Debt to Equity1.261.111.130.0600-1.27
Debt to Assets31.18%22.27%19.33%2.65%0.00%0.00%132.86%
Net Debt to EBITDA-0.510.07-0.22-16.980.671.08-3.79

BFRI Historical Efficiency Ratios

7 years
Metric (FY)TTM202420232022202120202019
Receivables Turnover8.337.026.63.876.375.735.47
Payables Turnover1.3410.031.9611.8819.365.991.72
Inventory Turnover6.542.81.62.122.861.281.18
Days Sales Outstanding43.8352.0155.394.2757.3163.6966.72
Days Payables Outstanding272.536.41186.3530.7218.8560.95212.21
Days of Inventory on Hand55.78130.37228.24172.3127.7285.49308.28

BFRI Historical Market Metrics

7 years
Metric (FY)TTM202420232022202120202019
Enterprise Value to EBITDA-3.96-0.35-0.453.77-2.83-5.75-10.36
Market Cap$19.46M$6.01M$4.28M$19.39M$128.63M$51.16M$53.54M
Enterprise Value$22.31M$5.03M$8.34M$3.52M$104.08M$43.08M$84.44M
Dividend Yield0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Payout Ratio0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Frequently Asked Questions

How does Biofrontera Inc.’s P/E ratio compare with its history?

On this page, you can use the latest P/E (from the Key Ratios table) as your starting point and compare it to the company's multi-year P/E range in the historical rows. When the current P/E sits near its historical average, the multiple is close to that range. Look at trend direction in profitability and cash-flow rows, plus liquidity and leverage, rather than treating the P/E in isolation.

What is Biofrontera Inc. market cap?

Market cap is the market value of a company's equity and is commonly calculated as share price multiplied by shares outstanding. The latest market cap shown in the table is $19.46M. Pair market cap with valuation multiples (P/E, P/B, P/S) so you can evaluate whether size also corresponds with "quality" and profitability. For a wider view across stocks, you can also use the stock screener.

How does Biofrontera Inc.’s P/E compare with its industry?

There is no P/E Tickerplace rates as good. Compare the P/E on this page with Biofrontera Inc.'s own historical range (in the table) and with peers via the Screener and Compare tools. A higher or lower multiple versus peers is a calculated gap, not a recommendation.

How does Biofrontera Inc. compare to its competitors in key financial ratios?

The fastest way to compare Biofrontera Inc. with competitors is to use the built-in "Peers Comparison" section on this page and the Compare tool. Focus on a small set of ratios that work together: P/E for valuation, ROE/ROIC for profitability and capital efficiency, current ratio and interest coverage for liquidity and solvency, and debt-to-equity for leverage risk. When you see Biofrontera Inc. outperform peers on profitability while keeping valuation and leverage reasonable, it often signals stronger fundamentals.

What do Biofrontera Inc.'s liquidity and leverage ratios show?

Liquidity and leverage figures on this page are published ratios, not a verdict that Biofrontera Inc. is financially strong. Current ratio is about 1.18, which is above 1.0 and can indicate more comfortable short-term liquidity. Interest coverage is about -18.81, implying less buffer for servicing interest costs. Debt-to-equity is about 1.26, suggesting leverage is more moderate relative to a high-debt profile. Pair them with ROE/ROIC and cash-flow rows in the table. Tickerplace does not rate the company as a good or poor investment.

What do Biofrontera Inc.'s financial ratios say about its future growth?

Ratios are a way to see what the business is likely to sustain. Look for upward trends in profitability metrics (ROE and ROIC), improving earnings/cash-flow backed measures, and stable or strengthening liquidity. If Biofrontera Inc. is sustaining strong returns (for example ROE at -127.78% and ROIC at -31.18%) while debt levels and interest coverage remain manageable, growth expectations may be more credible. If valuation multiples expand while returns weaken, the market may be pricing optimistic growth ahead of results.